Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 3/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22791369 | 1.00 | PTGER4 (0.53) | PTGER4PTGDR2SLC6A5DRD4HCRTR1 | |
| SCHEMBL29614446 | 1.00 | PTGER4 (0.53) | PTGER4PTGDR2SLC6A5DRD4HCRTR1 | |
| SCHEMBL22777272 | 0.91 | PTGER4 (0.51) | PTGER4PTGDR2DRD4SIGMAR1ROCK2 | |
| SCHEMBL29614541 | 0.91 | PTGER4 (0.51) | PTGER4PTGDR2DRD4SIGMAR1ROCK2 | |
| SCHEMBL22776476 | 0.91 | PTGER4 (0.51) | PTGER4PTGDR2DRD4SIGMAR1ROCK2 | |
| SCHEMBL22791361 | 0.90 | PTGER4 (0.45) | PTGER4PTGDR2SLC6A5HCRTR1HCRTR2 | |
| SCHEMBL22791289 | 0.89 | PTGDR2 (0.41) | PTGER4PTGDR2SLC6A5DRD4SIGMAR1 | |
| SCHEMBL22791152 | 0.89 | PTGDR2 (0.41) | PTGER4PTGDR2SLC6A5DRD4SIGMAR1 | |
| SCHEMBL22791290 | 0.89 | PTGDR2 (0.41) | PTGER4PTGDR2SLC6A5DRD4SIGMAR1 | |
| SCHEMBL22776526 | 0.88 | PTGER4 (0.51) | PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324803-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3983412-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020251957-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324803-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGDR2 7/4885SLC6A5 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.